People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
People in rural areas are at greater risk of developing chronic obstructive pulmonary disease (COPD) due to a variety of factors. We explain why.
Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously ...
Lung ultrasound (LUS) may be an effective screening tool for interstitial lung disease in patients with asymptomatic rheumatoid arthritis.
The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...
"We are thrilled to welcome Dr. Kokoszynska to our team," said Patrick A. Taylor, York Hospital president and CEO. "Her ...
Prospective study on abemaciclib-induced interstitial lung disease in metastatic breast cancer reveals a 7.4% incidence rate.
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback